Puma Biotechnology traded at $5.70 this Friday February 27th, decreasing $1.90 or 25.00 percent since the previous trading session. Looking back, over the last four weeks, Puma Biotechnology lost 9.81 percent. Over the last 12 months, its price rose by 59.22 percent. Looking ahead, we forecast Puma Biotechnology to be priced at 6.62 by the end of this quarter and at 6.02 in one year, according to Trading Economics global macro models projections and analysts expectations.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to improve cancer care. The Company's products include PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357, as well as certain related compounds. Its lead product, NERLYNX, is an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI), that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment for patients with HER2-positive metastatic breast cancer. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors. The Company has two subsidiaries: Puma Biotechnology Ltd and Puma Biotechnology, B.V.